TRex Bio
TRexBio is a clinical-stage biotechnology company developing tissue-targeted regulatory T cell (Treg) therapeutics for autoimmune and inflammatory diseases, with lead candidate TRB-061 (a TNFR2 agonist) in Phase 1 trials for atopic dermatitis.
- Company typePrivate
- Founded2018
- HeadquartersSouth San Francisco, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What TRex Bio does
TRex Bio, Inc. (TRexBio) is a clinical-stage biotechnology company founded in 2018 and headquartered in South San Francisco, California. The company develops tissue-targeted regulatory T cell (Treg) therapeutics for autoimmune and inflammatory diseases, with stated focus areas in dermatology and gastroenterology. Its lead wholly owned candidate, TRB-061, is a novel TNFR2-selective agonist biologic in Phase 1a/1b clinical development for moderate-to-severe atopic dermatitis, with sixteen-week Phase 1b data anticipated in the first half of 2027. Additional wholly owned preclinical programs TRB-071 and TRB-081 are advancing toward Phase 1 trials expected in 2027, and partnered programs TRB-041 and TRB-051 have been licensed to Eli Lilly.
The company's core technology is its proprietary Deep Biology Platform, which decodes human tissue Treg behavior using computational biology, functional genomics, and high-resolution transcriptomic mapping. Central assets include a Treg Atlas capturing approximately 1,000 tissue Treg-enriched genes, a proprietary human tissue bank, and a phenotypic assay cascade designed to test targets across multiple donors and inflammatory contexts for translational validation. TRB-061 is differentiated mechanistically by its ability to selectively activate and expand effector Tregs in tissue without engaging macrophages, NK cells, or effector T cells.
TRexBio is pre-revenue and operates under a biopharmaceutical development revenue model, with future revenue expected from product sales and licensing royalties upon regulatory approval. The company has raised approximately $219 million across four funding rounds (2021 Series A, 2022 Series A extension, 2024 Series B, 2026 Series B extension) from a syndicate including Eli Lilly, Johnson & Johnson Innovation, Pfizer Ventures, Polaris Partners, SV Health Investors, Janus Henderson, Balyasny, and Affinity Asset Advisors. Go-to-market involves advancing wholly owned candidates through clinical trials independently while partnering select programs with major pharmaceutical companies.
TRex Bio firmographics
Firmographics- Name
- TRex Bio
- Legal name
- TRex Bio, Inc.
- Website
- https://trex.bio
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- TRexBio is a clinical-stage biotechnology company developing tissue-targeted regulatory T cell (Treg) therapeutics for autoimmune and inflammatory diseases, with lead candidate TRB-061 (a TNFR2 agonist) in Phase 1 trials for atopic dermatitis.
- Ownership category
- akta.pro rank
TRex Bio industry classification
Industry- Product category
- Immunology Therapeutics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Immunology & Inflammation Pharmaceuticals (HLAIAAAD)
- akta.pro secondary industries
- Dermatology Specialty Pharmaceuticals (HLAIACAL), Gastroenterology Specialty Pharmaceuticals (HLAIACAE), Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)
Keywords
Where TRex Bio is headquartered
LocationHeadquarters
- HQ city
- South San Francisco
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
TRex Bio business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Biopharmaceutical Development: As a clinical-stage biotechnology company, TRexBio generates no current revenue. The company is focused on developing novel therapeutics through clinical trials with the intent to commercialize pipeline programs upon regulatory approval. Revenue will be derived from product sales following successful clinical development and regulatory approval.
Go-to-market motion1 record
Marketing channels4 records
TRex Bio product offering
Product offeringCore offering
TRexBio develops tissue-targeted regulatory T cell (Treg) biologics for autoimmune and inflammatory diseases, anchored by its proprietary Deep Biology Platform that maps human tissue Treg behavior using computational biology and functional genomics. The lead wholly owned candidate, TRB-061 (a TNFR2-selective agonist), is in Phase 1 clinical trials for moderate-to-severe atopic dermatitis, with additional wholly owned programs (TRB-071, TRB-081) in preclinical development and partnered programs (TRB-041, TRB-051) licensed to Eli Lilly.
Product overview
TRexBio is a clinical-stage biotechnology company developing a pipeline of biologics focused on tissue-targeted regulatory T cell (Treg) therapeutics for autoimmune and inflammatory diseases. The company's proprietary Deep Biology Platform serves as the core discovery engine, mapping human tissue Treg behavior to identify novel therapeutic targets. The lead wholly owned product is TRB-061, a TNFR2 agonist in Phase 1 clinical trials for atopic dermatitis. The pipeline also includes preclinical programs TRB-071 and TRB-081 advancing toward clinical trials in 2027, plus partnered programs TRB-041 and TRB-051 with Eli Lilly. The company leverages partnerships with Johnson & Johnson Innovative Medicine for additional immunology targets.
Differentiator
Problem solved
Functional benefit
Products and services
- Deep Biology Platform
Quantifiable outcome
- TRB-061 demonstrated selective Treg activity in vitro and pharmacodynamic expansion of tissue-licensed effector Tregs in non-human primates
Companies that use TRex Bio
Customer profileSegments1 record
Ideal customer profiles2 records
TRex Bio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature4 records
TRex Bio partnerships and signals
Strategic signalScale indicators3 records
Recent moves6 records
Expansion highlights5 records
TRex Bio competitors and assessment
Company assessmentDirect peers
- Sonoma Biotherapeutics: Clinical-stage Treg cell therapy company developing engineered regulatory T cells for autoimmune and inflammatory diseases. Directly comparable as a Treg-focused immunology biotech with a similar clinical-stage profile and autoimmune disease focus.
- Abata Therapeutics: Treg cell therapy biotech developing engineered regulatory T cells for autoimmune diseases. Comparable as a Treg-focused immunology platform with similar therapeutic area and stage of development.
- GentiBio: Engineered Treg cell therapy company focused on inflammatory and autoimmune diseases. Directly comparable as a Treg-modulating immunology platform addressing autoimmune indications.
- Kyverna Therapeutics: Clinical-stage cell therapy company developing CAR-Treg therapies for autoimmune diseases. Comparable as a Treg-focused immunology platform with overlapping autoimmune disease targets.
- Anokion: Immune tolerance biotech using engineered antigen-specific approaches for autoimmune diseases. Comparable as an immune-tolerance platform in autoimmune disease with overlapping mechanistic ambitions.
Broad incumbents
- Bristol-Myers Squibb: Large pharma with a major immunology franchise (Zeposia, Sotyktu) and significant autoimmune disease commercial infrastructure. Comparable as a broad incumbent in immunology with overlapping therapeutic targets.
- AbbVie: Large pharma dominating immunology with Humira, Rinvoq, and Skyrizi across multiple autoimmune indications. Comparable as a broad incumbent shaping the autoimmune disease competitive landscape that TRexBio's pipeline would enter.
- Sanofi: Large pharma with Dupixent (with Regeneron) — the dominant atopic dermatitis therapy — and a broader immunology portfolio. Most directly relevant incumbent due to overlap with TRexBio's lead indication.
Emerging players
- Arcutis Biotherapeutics: Commercial-stage dermatology biotech developing topical therapies for inflammatory skin diseases including atopic dermatitis. Comparable as a smaller dermatology-focused player in the same disease area as TRexBio's lead program.
Others
- Eli Lilly: TRexBio's largest investor and partner, having licensed multiple programs from the Deep Biology Platform. Comparable as a major immunology pharma incumbent and key ecosystem participant in TRexBio's commercial pathway.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
TRex Bio social profiles
Digital presenceTRex Bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
TRex Bio leadership team
Management profileNumber of profiles
Profiles17 records
TRex Bio funding detail
Funding detailFunding overview
Funding rounds4 records
Investors15 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
TRex Bio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about TRex Bio
What does TRex Bio do?
TRexBio develops tissue-targeted regulatory T cell (Treg) biologics for autoimmune and inflammatory diseases, anchored by its proprietary Deep Biology Platform that maps human tissue Treg behavior using computational biology and functional genomics. The lead wholly owned candidate, TRB-061 (a TNFR2-selective agonist), is in Phase 1 clinical trials for moderate-to-severe atopic dermatitis, with additional wholly owned programs (TRB-071, TRB-081) in preclinical development and partnered programs (TRB-041, TRB-051) licensed to Eli Lilly.
Is TRex Bio a public or private company?
TRex Bio is a private company. It is classified as venture growth investor backed and is currently operating.
When was TRex Bio founded?
TRex Bio was founded in 2018. It employs 11 to 50 people.
Where is TRex Bio based?
TRex Bio is headquartered in South San Francisco, United States, in the North America region.
How does TRex Bio make money?
One revenue line is on record: biopharmaceutical Development.
Who are TRex Bio's main competitors?
Direct peers on record are Sonoma Biotherapeutics, Abata Therapeutics, GentiBio, Kyverna Therapeutics and Anokion. Broad incumbents are Bristol-Myers Squibb, AbbVie and Sanofi. Arcutis Biotherapeutics is listed as an emerging player. Eli Lilly is listed as an others.
Does TRex Bio have an API?
No public API is recorded for TRex Bio.
What industry is TRex Bio in?
TRex Bio's product category is Immunology Therapeutics. Its primary akta.pro industry code is HLAIAAAD, Immunology & Inflammation Pharmaceuticals, with a secondary code of HLAIACAL, Dermatology Specialty Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2836.